06 Nov AurorA-TT’s call to align the technology transfer ecosystem in Italy received a solid answer from Universities, IRCCS and research centers (English version)
For the first time in Italy, scientific research aligns into a common strategy to foster the birth of a Venture Capital fund fully dedicated to biotechnology.
Milan (Italy), November 6th, 2017.
In May 2017, AurorA-TT announced the launch of a Venture Capital fund fully dedicated to biotechnology applying, through selected fund raising channels, for the management of 50M€.
The first challenge was then to align the Italian scientific research ecosystem. In less than four months, the answer has been extraordinary with 22 between Universities, IRCCS and research centers adhering to AurorA-TT’s initiative. From University of Turin, University of Milan, Ferrara and Rome, University Cattolica S.C., IRCCS Regina Elena, ENEA to the Sicilian Fondazione RI.MED.
Dr. Guido Guidi, co-founder, chairman and managing partner of AurorA-TT commented: “I have worked for years abroad in multi-national pharmaceutical companies, the Italian research ecosystem has always been percieved as scientifically solid but fragile in its essence because, unlike what happens in other countries, it is patchy with fragmented resources. When I decided to move back to Italy I accepted the challenge to ameliorate such ecosystem proposing a long-term strategy to align the italian scientific research into a sort of national Research and Development department, unique in the world and more competitive than any other company in the sector. I honestly was not expecting such a warm response form the scientific community. Today there are all the premises needed to translate science into industry and to offer a concrete possibility to that many italian scientists that each year decide to find better structured positions abroad.
AurorA-TT’s partners: Università degli Studi Milano, Università degli Studi di Torino, Università degli Studi di Firenze, Università degli Studi di Roma Tor Vergata, Università degli Studi di Pavia, Università degli Studi di Parma, Università degli Studi di Ferrara, Università degli Studi di Verona, Università degli Studi di Padova, Università degli Studi di Bari, Università Cattolica del Sacro Cuore, Università Campus Biomedico, Enea, BioIndustry Park Silvano Fumero, Istituto Nazionale dei Tumori Regina Elena, Istituto San Gallicano, Istituto Pasteur, Istituto Nazionale di Genetica Molecolare, Fondazione Ri.Med, PNI Cube e Cluster Lombardia Life Sciences (one of our partner prefers not to be mentioned).
AurorA-TT is a Technology Transfer Intermediation Company established in 2017 based in Milan, Italy. We identify promising scientific breakthroughs from academic and research centers in Italy and partner with academia, research institutions and biotech companies based globally.
We do invest in pre-seed and seed projects to bridge the gap between basic research and industrial drug development with industrial discipline.
Successful projects either become assets for the creation of stand-alone companies, partnerships with financial investors, biotech and pharma companies or translate into agreements of varying nature with synergic partners.
For further information:
telephone +39 02 9475 8489
e-mail web www.aurora-tt.com